Starscope: Does Starscope Monocular Really Work for Stargazing & Hiking? Read Full Starscope Monocular Telescope Consumer Report!
San Diego, CA, May 31, 2025 (GLOBE NEWSWIRE) -- Introduction: Why the…
JAMining Expands FCA-Regulated Cloud Mining Services Amid Surging Crypto Market Activity
Image by JAMining LONDON, May 31, 2025 (GLOBE NEWSWIRE) -- JAMining, a…
PAIRMiner Makes Bitcoin Mining More Accessible Amid Market Surge
Image by PAIRMiner STUTTGART, Germany, May 31, 2025 (GLOBE NEWSWIRE) -- As…
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer
Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a…
New data show Roches Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer
The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than…
Libtayo (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing
Libtayo demonstrated a 68% reduction in the risk of disease recurrence or…
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde regimen in metastatic pancreatic adenocarcinoma
Phase III NAPOLI 3 trial is the largest and has the longest…
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33…
New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
More than half of residents with tardive dyskinesia (TD) residing in long-term…
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TE
Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence…